Literature DB >> 17579022

Heterogeneity of effector phenotype for acute phase and memory influenza A virus-specific CTL.

Misty R Jenkins1, Katherine Kedzierska, Peter C Doherty, Stephen J Turner.   

Abstract

Ag-specific, CD8+ CTLs clear influenza A viruses from the lung via granzyme (Gzm) and perforin-dependent mechanisms. Ex vivo analysis of perforin-Gzm mRNA profiles demonstrated substantial heterogeneity in patterns of effector mRNA transcription of CD8+ D(b)NP(366)- or D(b)PA(224)-specific CTL. The only difference between the two epitope-specific sets was apparent very early after infection with similar molecular profiles seen in peak primary and secondary responses and in long-term memory. Surprisingly, memory T cells also expressed a diverse pattern of effector mRNA profile with an emphasis on GzmB and, surprisingly, GzmK. This analysis thus defines how naive, effector, and memory T cells differ in cytotoxic potential and provides novel insight into the molecular signatures of effector molecules observed at various stages after infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579022     DOI: 10.4049/jimmunol.179.1.64

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Interleukin-1R signaling is essential for induction of proapoptotic CD8 T cells, viral clearance, and pathology during lymphocytic choriomeningitis virus infection in mice.

Authors:  Lars T Joeckel; Reinhard Wallich; Sunil S Metkar; Christopher J Froelich; Markus M Simon; Christoph Borner
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

2.  Primary CTL response magnitude in mice is determined by the extent of naive T cell recruitment and subsequent clonal expansion.

Authors:  Nicole L La Gruta; William T Rothwell; Tania Cukalac; Natasha G Swan; Sophie A Valkenburg; Katherine Kedzierska; Paul G Thomas; Peter C Doherty; Stephen J Turner
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

Review 3.  Aging, cytomegalovirus (CMV) and influenza vaccine responses.

Authors:  Daniela Frasca; Bonnie B Blomberg
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

4.  Phenotypic and functional profiling of malaria-induced CD8 and CD4 T cells during blood-stage infection with Plasmodium yoelii.

Authors:  Anmol Chandele; Paushali Mukerjee; Gobardhan Das; Rafi Ahmed; Virander S Chauhan
Journal:  Immunology       Date:  2010-10-29       Impact factor: 7.397

5.  Finding multiple needles in one immune haystack.

Authors:  Katherine Kedzierska; John Stambas; Peter C Doherty
Journal:  Nat Methods       Date:  2009-07       Impact factor: 28.547

6.  CD8 T cells utilize TRAIL to control influenza virus infection.

Authors:  Erik L Brincks; Arna Katewa; Tamara A Kucaba; Thomas S Griffith; Kevin L Legge
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

7.  Repetitive peptide boosting progressively enhances functional memory CTLs.

Authors:  Kendra Smyth; Karla Garcia; Zhifeng Sun; Wenbin Tuo; Zhengguo Xiao
Journal:  Biochem Biophys Res Commun       Date:  2012-07-15       Impact factor: 3.575

8.  Chemokine Signatures of Pathogen-Specific T Cells I: Effector T Cells.

Authors:  Jens Eberlein; Bennett Davenport; Tom T Nguyen; Francisco Victorino; Kevin Jhun; Verena van der Heide; Maxim Kuleshov; Avi Ma'ayan; Ross Kedl; Dirk Homann
Journal:  J Immunol       Date:  2020-09-18       Impact factor: 5.422

9.  Chemokine Signatures of Pathogen-Specific T Cells II: Memory T Cells in Acute and Chronic Infection.

Authors:  Bennett Davenport; Jens Eberlein; Tom T Nguyen; Francisco Victorino; Verena van der Heide; Maxim Kuleshov; Avi Ma'ayan; Ross Kedl; Dirk Homann
Journal:  J Immunol       Date:  2020-09-18       Impact factor: 5.422

10.  Predicting CD62L expression during the CD8+ T-cell response in vivo.

Authors:  Timothy E Schlub; Vladimir P Badovinac; Jaime T Sabel; John T Harty; Miles P Davenport
Journal:  Immunol Cell Biol       Date:  2009-10-27       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.